Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Acrobiosystems CoSZSE:301080 +6.36%91 PS Ratio is 14.90 as of Sep. 02, 2026, which is 18% above its 10-year median of 12.60. GuruFocus rates SZSE:301080 with a GF Score™ of 91/100 and a GF Value™ of ¥57.29 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 937 Biotechnology companies, Acrobiosystems Co ranks worse than 60.19% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Acrobiosystems Co's share price is ¥84.65.
Acrobiosystems Co's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 was ¥5.68. Hence, Acrobiosystems Co's PS Ratio for today is 14.90.
The historical rank and industry rank for Acrobiosystems Co's PS Ratio or its related term are showing as below:
SZSE:301080'
s PS Ratio Range Over the Past 10 Years
Min: 6.59 Med: 12.6 Max: 40.6
Current: 14.89
During the past 9 years, Acrobiosystems Co's highest PS Ratio was 40.60. The lowest was 6.59. And the median was 12.60.
SZSE:301080's PS Ratio is ranked worse than 60.19% of 937
companies
in the Biotechnology industry
Industry Median: 9.54
vs SZSE:301080: 14.89
During the past 12 months, the average Revenue per Share Growth Rate of Acrobiosystems Co was 29.70% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 21.00% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 22.70% per year.
During the past 9 years, Acrobiosystems Co's highest 3-Year average Revenue per Share Growth Rate was 51.00% per year. The lowest was 18.30% per year. And the median was 29.40% per year.
Acrobiosystems Co (SZSE:301080) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Acrobiosystems Co PS Ratio Related Terms
Acrobiosystems Co PS Ratio Historical Data
* Premium members only.
The historical data trend for Acrobiosystems Co's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SZSE:301080 vs VRTX, REGN, MRNA: PS Ratio Comparison
For the Biotechnology subindustry, Acrobiosystems Co's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Acrobiosystems Co PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Acrobiosystems Co's PS Ratio distribution charts can be found below:
* The bar in red indicates where Acrobiosystems Co's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Acrobiosystems Co's Share Price of today is ¥84.65. Acrobiosystems Co's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥5.68.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Acrobiosystems Co (SZSE:301080) has a PS Ratio of 14.90 as of Sep. 02, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Acrobiosystems Co and its competitors. This is 18% above median its historical median of 12.60. Over the past decade, Acrobiosystems Co's PS Ratio has ranged from 6.59 to 40.60. According to the industry distribution chart, Acrobiosystems Co ranks #564 out of 937 companies in the Biotechnology industry, placing it in the top 60.2%.
Is Acrobiosystems Co's PS Ratio too high?
Acrobiosystems Co's current PS Ratio of 14.90 is 18% above median its 10-year median of 12.60. Over the past 10 years, this metric has ranged from a low of 6.59 to a high of 40.60. The Biotechnology industry median PS Ratio is 9.54. Acrobiosystems Co's value of 14.90 is 56.2% above this industry median. Based on the distribution chart, Acrobiosystems Co ranks #564 out of 937 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Acrobiosystems Co has a GF Score™ of 91/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Acrobiosystems Co's PS Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Acrobiosystems Co ranks #564 out of 937 companies for PS Ratio. This places Acrobiosystems Co in the lower half of its industry. The industry median PS Ratio is 9.54. Acrobiosystems Co's value of 14.90 is 56.2% above this benchmark. Historically, Acrobiosystems Co's own PS Ratio has ranged from 6.59 to 40.60 over the past decade. While the company's 10-year median is 12.60 vs. the industry median of 9.54, Acrobiosystems Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.54, based on 937 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Acrobiosystems Co's current PS Ratio of 14.90 is 56.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Acrobiosystems Co and its competitors. For the Biotechnology industry, the median PS Ratio is 9.54 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Acrobiosystems Co's current PS Ratio is 14.90, which is 18% above median its own 10-year median of 12.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Acrobiosystems Co stock overvalued right now?
Based on GuruFocus' analysis, Acrobiosystems Co (SZSE:301080) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥57.29, compared to a current price of ¥84.65 — trading 47.8% above its estimated fair value. The current PS Ratio is 14.90, which is 18% above median its 10-year median of 12.60 and 56.2% above the Biotechnology industry median of 9.54. Acrobiosystems Co's overall GF Score™ is 91/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Acrobiosystems Co (SZSE:301080), the current PS Ratio is 14.90 as of Sep. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Acrobiosystems Co (SZSE:301080) Overvalued in 2026?
Based on GuruFocus' analysis, Acrobiosystems Co stock appears to be overvalued.
The current stock price of ¥84.65 is trading 47.8% above its estimated GF Value™ of ¥57.29.
GuruFocus considers Acrobiosystems Co to be Significantly Overvalued.
Key valuation signals for SZSE:301080:
PS Ratio: 14.90 (18% above median its 10-year median of 12.60)
GF Value™: ¥57.29 vs. price of ¥84.65 (47.8% above fair value)
Industry Position: 56.2% above the Biotechnology median (#564 of 937)
No single metric tells the full story. See the SZSE:301080 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Acrobiosystems Co Ltd is a global brand focusing on protein technology, products and services in the development of biological drugs. It is committed to providing target antigens and other key reagents and related services required in the development of targeted therapeutic drugs.
91GF Score
Get the complete analysis for SZSE:301080
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SZSE:301080 has been successfully added to your 
